The Filing Desk

Qiagen

QGEN · NYSE · Health Care · Financials, fiscal 2016 to 2025

QGEN · Last close · November 19, 2026
$49.63

Qiagen's revenue rose 5.7% to $2.1 billion in fiscal 2025. Its operating margin was 22.3%, up from 4.9% a year earlier. Free cash flow was $453 million, down 10.5%. It paid out $334 million in dividends and buybacks, 74% of free cash flow. The diluted share count fell 2.6%.

QIAGEN N.V. Latest fiscal year ended December 31, 2025 20-F filed March 20, 2026 · 0001015820-26-000018 Updated
Revenue
$2.1B
5.7%
Operating margin
22.3%
17.3 pts
Net income
$425M
408.3%
Free cash flow
$453M
10.5%
Return on capital
9.9%
8.2 pts

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

About these figures. Qiagen is a foreign company: it files an annual report on Form 20-F, prepared under US accounting standards (US GAAP), instead of a 10-K, and no quarterly reports, so this page has fiscal years only. Its shares trade in the US as American depositary shares (ADSs), and one ADS can stand for several ordinary shares, so per-share figures are per ordinary share and the page has no market value, P/E or valuation model.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 21.3% a year and net income 20.3% a year, as buybacks cut the share count by 8%.

Diluted earnings per share
US$ per ordinary share, fiscal years; loss years in red. One US-listed ADS can stand for several ordinary shares.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,0651,4181,0581,1531,099
Debt incl. finance leases1,9421,8611,5101,3921,654
Net debt (negative means net cash)876443452238556
Net debt to EBITDA1.0x0.6x0.7x0.8x0.8x
Debt to equity0.6x0.5x0.4x0.4x0.4x
Interest coverage11.6x9.1x7.7x2.2x14.0x
Current ratio1.4x2.5x2.0x1.9x3.9x
Quick ratio1.2x2.1x1.6x1.6x3.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 96 of 98 of 9
Rule of 407.5%26.2%27.3%
Altman Z''4.644.345.06
Accruals ratio−1.9%−10.0%−3.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassFail
Current ratio roseFailFailPass
Share count didn't riseFailPassPass
Gross margin roseFailFailPass
Revenue rose relative to assetsFailPassPass
F-score4 of 96 of 98 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Qiagen side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
QiagenFY255.7%22.3%21.7%9.9%0.8x8
MedpaceFY2520.0%21.1%26.9%—−0.9x4Compare
Bio-Rad LaboratoriesFY250.7%1.8%14.5%0.5%−1.6x5Compare
WatersFY257.0%25.4%17.1%21.0%0.8x6Compare
Bio-TechneFY26−0.4%20.7%21.7%9.2%−0.2x9Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue1,3381,4181,5021,5261,8702,2522,1421,9651,9782,090
Revenue growth4.5%6.0%6.0%1.6%22.5%20.4%−4.9%−8.2%0.7%5.7%
Gross profit8459231,0011,0051,2331,4511,3851,2349671,300
Research and development150154162157149190190198194188
Operating income99153267−2638663053241098466
Net income8040190−4235951342334184425
Diluted EPS (US$)0.340.170.82−0.181.532.211.841.480.371.94
Diluted shares (millions)239233234227234232230231225219
Cash flow
Cash from operations342287360331458639715460674654
Capital expenditure7490110118133190129150167201
Free cash flow267197250213325449586310506453
Dividends paid00000000054
Share buybacks061105746410000292280
Acquisitions9050173682400641500291
Stock-based compensation28344066413850474450
Balance sheet at fiscal year end
Cash and short-term investments5321,0171,3947537151,0651,4181,0581,1531,099
Debt incl. finance leases1,0671,7582,1741,7061,9231,9421,8611,5101,3921,654
Total assets4,3085,0385,7485,2365,8706,1476,2886,1155,6906,281
Total liabilities1,7012,4983,1132,6993,0723,0502,8212,3072,1222,503
Shareholders' equity2,6072,5412,6352,5372,7983,0963,4673,8083,5673,778
Margins and ratios
Gross margin63.1%65.1%66.7%65.9%65.9%64.4%64.7%62.8%48.9%62.2%
Operating margin7.4%10.8%17.8%−1.7%20.7%28.0%24.8%20.9%4.9%22.3%
Net margin6.0%2.9%12.7%−2.7%19.2%22.8%19.8%17.4%4.2%20.3%
Free cash flow margin20.0%13.9%16.6%13.9%17.4%19.9%27.4%15.8%25.6%21.7%
Rule of 40 (growth + FCF margin)24.4%19.8%22.6%15.6%39.9%40.3%22.5%7.5%26.2%27.3%
Return on capital3.1%2.4%6.7%−0.6%8.4%12.9%11.1%8.0%1.7%9.9%
Return on equity3.1%1.6%7.4%−1.6%13.5%17.4%12.9%9.4%2.3%11.6%
Return on assets1.9%0.9%3.5%−0.8%6.5%8.5%6.8%5.5%1.4%7.1%
Net debt to EBITDA1.7x2.0x1.6x4.6x2.0x1.0x0.6x0.7x0.8x0.8x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Qiagen's Form 20-F filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Qiagen.